- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
BlackRock Health Sciences Trust II(BMEZ)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for BMEZ
11/13/2026: BMEZ (2-star) has a low Upturn Star Rating. Not recommended to BUY.
BlackRock Health Sciences Trust II is a closed-end management investment fund that provides exposure to global healthcare and life sciences equities alongside an option-writing income strategy. The fund benefits from BlackRock's institutional research capabilities and secular demographic tailwinds supporting medical innovation. However, it faces risks related to healthcare regulatory changes, sector concentration, and potential market-price discounts to its net asset value. It is well-suited for income-oriented investors seeking targeted healthcare exposure through professional management. Key developments to monitor include distribution coverage stability and fluctuations in the fund's discount to NAV.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | While it invests in innovative healthcare and biotech growth companies, its closed-end structure and income focus dilute pure capital appreciation. |
| Momentum investor | Weak fit | The fund moves sluggishly compared to individual momentum stocks due to its diversified multi-asset holdings and discount volatility. |
| Value investor | Strong fit while signal remains positive | Purchasing shares at a wide discount to net asset value can offer an attractive margin of safety for value-oriented buyers. |
| Dividend investor | Strong fit | The fund targets regular distribution income derived from portfolio dividends and option premium strategies. |
| Low-risk investor | Weak fit | High sector concentration in healthcare and biotech introduces significant clinical trial and regulatory volatility. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Medium / high | The fund experiences swings driven by both healthcare stock fluctuations and shifts in its market-price premium or discount to NAV. |
| Valuation risk | Medium | Buying shares when the discount to NAV narrows or turns into a premium can reduce prospective total returns. |
| Competition risk (name the main competitor theme, e.g. AI competition) | Medium | Alternative healthcare closed-end funds and low-fee sector ETFs compete directly for investor capital and yield seekers. |
| Business quality | Strong | The fund provides professional management backed by BlackRock's institutional framework and rigorous research capabilities. |
| Dividend income | Medium / high | Distributions depend on option premiums and realized gains, which can vary depending on market conditions. |
| Execution risk | Medium | Portfolio managers must successfully navigate complex clinical readouts and regulatory approvals across individual holdings. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.07B USD | Price to earnings Ratio 5.07 | 1Y Target Price - |
Price to earnings Ratio 5.07 | 1Y Target Price - | ||
Volume (30-day avg) 168.5K shares | Beta - | 52 Weeks Range 12.95 - 17.85 | Updated Date 11/15/2026 |
52 Weeks Range 12.95 - 17.85 | Updated Date 11/15/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 3.39 |
Sector & Industry Intelligence
Sector
Financial Services
Constructive- Sentiment
- Bullish
- Momentum
- BUY Breadth Improving
- BUY participation
- 50.4%
- Active BUY / eligible
- 61 / 121
- 30-Day BUY Count Change
- +45
- Market state
- Bullish
More qualifying stocks are receiving or maintaining BUY advisories, indicating improving market participation.
Industry
Asset Management
- BUY participation
- 52.9%
- Active BUY / eligible
- 9 / 17
- 30-Day BUY Count Change
- +3
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.

Very Smooth
The stock has followed a highly orderly price path with minimal short-term disruption.
Analysis of Past Performance
Type Stock | Historic Profit 45.97% | Avg. Invested days 84 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Portfolio Investment Income | Dividends and interest received from underlying healthcare, pharmaceutical, and medical device equities. | The fund earns baseline cash flow from the dividends paid by the companies it owns. |
| Option Premium Generation | Cash premiums collected from writing covered call options on selected portfolio securities. | Additional income is generated by selling call options against portions of the equity portfolio. |
Valuation
Trailing PE 5.07 | Forward PE - | Enterprise Value - | Price to Sales(TTM) 5.03 |
Enterprise Value - | Price to Sales(TTM) 5.03 | ||
Enterprise Value to Revenue 5.03 | Enterprise Value to EBITDA - | Shares Outstanding 62.50M | Shares Floating - |
Shares Outstanding 62.50M | Shares Floating - | ||
Percent Insiders 0.02 | Percent Institutions 28.16 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

